Scientific Reviews
Product Guides
Blogs
Topics
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!2025-02-06
105 Results for "
RNA structures
" in MedChemExpress (MCE) Product Catalog:
Products (105)
105 Results for "RNA structures" in MCE Product Catalog:
Cat. No.: HY-183383
CAS No.: 144303-74-2
Synonyms: 4-Thio-DU CEP
Target:
Research Areas:
4-Thio-dU CE phosphoramidite (4-Thio-DU CEP) is a special modified nucleotide unit of thymine/uracil structure, used in solid-phase oligonucleotide synthesis to introduce the protected 4-sulfur carbonyl group into the DNA or RNA chain. 4-Thio-dU CE phosphoramidite is mainly used for photocrosslinking, photophilic labeling, nucleic acid structure research, and site-specific functionalization through sulfur atoms after synthesis.
DMA-132 is a translation inhibitor and antiviral agent. DMA-132 can target and bind to the conserved RNA stem-loop (bulge structure) in the 5'-UTR of SARS-CoV-2, thereby blocking viral RNA translation and replication. DMA-132 can be used in research related to coronavirus disease 2019 (COVID-19) and coronavirus infections .
Cat. No.: HY-188020
Target:
Research Areas:
TAO-E Phosphoramidite is a phosphoramidite monomer with dual quenching properties for oligonucleotide synthesis. It contains a TAO anthraquinone quenching group, an ODMT protecting group, and a standard phosphoramidite structure. TAO-E Phosphoramidite can be used in RNA/DNA modification and fluorescent probe-related research.
Cat. No.: HY-181284
CAS No.: 2563902-57-6
Target:
G-quadruplex DNA/RNA Synthesis Ras PI3K Akt ERK Caspase Apoptosis
Research Areas:
BYBC‑1 is a selective G4‑RNA‑targeting ligand with high affinity forKRAS and NRAS G4‑RNAs (Kd = 0.05-0.28 μM). BYBC‑1 stabilizes G4‑RNA structures in KRAS and NRAS mRNA, blocks thePI3K/AKT and MAPK/ERK pathways, activates the DNA damage response (DDR), suppresses energy metabolism, and induces S‑phase arrest and apoptosis. BYBC‑1 exhibits high selectivity over non‑malignant fibroblasts and significantly inhibits the growth of HCT‑116 xenograft tumors in vivo. BYBC‑1 can be used for the study of colorectal cancer .
Cat. No.: HY-183980
Target:
Research Areas:
MJ-NR-27 is a bifunctional small molecule of ribonuclease-targeting chimera (RIBOTAC) that targets NRAS mRNA containing a G-quadruplex structure. MJ-NR-27 uses RNase L ligand 3 (HY-177030) as the RNase L ligand, RNA binder 4 (HY-183981) as the RNA binder, and Bis-PEG3-acid (HY-126891) as the linker. MJ-NR-27 achieves target RNA degradation by recruiting ribonuclease RNase L, and significantly induces morphological changes in tumor cells. MJ-NR-27 can be used in cancer research .
Cat. No.: HY-113138R
CAS No.: 2140-69-4
Synonyms: N3-Methyluridine (Standard)
Category:
Cat. No.: HY-103006R
CAS No.: 1612756-29-2
Research Areas:
NAI-N3 (Standard) is the analytical standard of NAI-N3 (HY-103006). This product is intended for research and analytical applications. NAI-N3 is a RNA acylation reagent that enables RNA purification. NAI-N3 is a dual-function SHAPE (selective 2-hydroxyl acylation and profiling experiment) probe (RNA structure probe and enrichment) . It contains an azide group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing alkyne groups. It can also undergo ring strain-promoted alkyne-azide cycloaddition (SPAAC) with molecules containing DBCO or BCN groups.
Cat. No.: HY-185993
Target:
Research Areas:
PT-IX Phosphoramidite is a non-nucleotide phosphoramidate reagent that can be used to introduce specific functional groups or modified structures during the synthesis of oligonucleotides. These modifications can confer special physical, chemical or biological properties to the synthesized DNA or RNA molecules, and are widely applied in molecular diagnostics, gene function research, and the development of therapeutic drugs such as nucleic acid aptamers.
Cat. No.: HY-188069
Target:
Research Areas:
C(F)U(OMe) Phosphoramidite is a dinucleotide phosphoramidite building block containing 2'-F and 2'-OMe modifications for introducing a C(F)-U(OMe) dinucleotide unit during oligonucleotide synthesis. C(F)U(OMe) Phosphoramidite can be used for modified oligonucleotide synthesis, RNA synthesis, and nucleic acid structure-function studies.
Cat. No.: HY-DY1111
CAS No.: 1539318-40-5
Target:
Research Areas:
DFHBI-2T solution is a membrane-permeable, RNA aptamer-activated fluorescent probe (Ex/Em=500 nm/523 nm), with a Kd value of 1300 nM for the RNA aptamer Spinach2. DFHBI-2T solution binds to Spinach2, converting the fluorophore to a fluorescent state, stabilizing its planar structure to facilitate the radiative fluorescence decay pathway, and forming a complex with red-shifted excitation and emission peaks. DFHBI-2T solution can be used for RNA imaging in live cells. It is also applicable to research related to fragile X-associated tremor/ataxia syndrome .
Solvent and concentration: DMSO: 5 mM
Solvent and concentration: DMSO: 5 mM
Cat. No.: HY-185928
CAS No.: 2659211-29-5
Target:
Research Areas:
Pinzodirsen (Compound ENTR-Oligo-0034) is a dystrophia myotonica protein kinase (DMPK) steric blocker. Pinzodirsen reduces the nuclear sequestration of toxic DMPK mRNA with splicing factors such as MBNL1 via steric blocking/relocation, or interferes with the secondary structure of CUG repeat RNA, instead of being cleaved by RNase H, thereby ameliorating systemic aberrant splicing in DM1. Pinzodirsen is applicable to the research of myotonic dystrophy .
Cat. No.: HY-DY2032
Target:
Research Areas:
Methyl Green Staining Solution (Chloroform-Extracted, 1%) is a basic dye stock solution with differential nucleic acid binding activity that distinguishes double-stranded DNA from RNA, and it can be used for assays related to nucleic acid distribution and DNA localization. Methyl Green Staining Solution (Chloroform-Extracted, 1%) functions by competitively binding to the phosphate groups of nucleic acids and stably binds to intact double-stranded DNA; RNA within the oocyte-specific ribonucleoprotein complex specifically binds to this dye, and RNase completely blocks this binding reaction. The nucleic acid recognition of Methyl Green Staining Solution (Chloroform-Extracted, 1%) depends on the size of the dye cation and the intact double-helical structure of DNA .
Cat. No.: HY-178671
CAS No.: 2734858-38-7
Target:
Research Areas:
CAP GAU m7G (5') ppp (5')(2'OMeA) pU is a trinucleotide cap analog with a Cap1 structure. CAP GAU m7G (5') ppp (5')(2'OMeA) pU can be co-transcriptionally incorporated into the 5' end of mRNA during T7 RNA polymerase-mediated in vitro transcription to form a natural Cap1 cap structure. CAP GAU m7G (5') ppp (5')(2'OMeA) pU enhances mRNA translation efficiency and reduces innate immune recognition, and it has been used in the preparation of self-amplifying mRNA rabies vaccines. CAP GAU m7G (5') ppp (5')(2'OMeA) pU can be applied to research related to in vitro mRNA transcription and mRNA vaccines .
Cat. No.: HY-139098A
CAS No.: 75252-12-9
Synonyms: m7Gp3G ammonium
Target:
Research Areas:
7-Methyl-diguanosine triphosphate (m7Gp3G) ammonium is an mRNA cap structure analog that inhibits in vitro protein synthesis by binding to the translation initiation complex. 7-Methyl-diguanosine triphosphate ammonium binds to eIF4E, promotes cap-dependent translation initiation, stabilizes mRNA, and acts as a translation enhancer. 7-Methyl-diguanosine triphosphate ammonium can be used to prepare synthetic capped RNA transcripts for studies related to mRNA translation, splicing, turnover, and intracellular transport .
Cat. No.: HY-L005
2,031 compounds
Epigenetics refers to changes in phenotype that are not rooted in DNA sequence. Many types of epigenetic processes have been identified, including DNA methylation, alteration in the structure of histone proteins and gene regulation by small noncoding microRNAs. Modification of DNA, protein, or RNA, resulting in changes to the function and/or regulation of these molecules, without altering their primary sequences, reveals the complexities of cellular differentiation, embryology, the regulation of gene expression, aging, cancer, and other diseases.
MCE provide a unique collection of 2,031 epigenetics-related compounds that can be used in the research of the related diseases.
Cat. No.: HY-178674
CAS No.: 531553-69-2
Research Areas:
Im-m7GDP is a capping reagent and also the P-imidazolide of N7-methylguanosine 5'-diphosphate. Im-m7GDP introduces an m7G cap structure to the monophosphate group of branched oligoribonucleotides, and is used in nucleic acid synthesis-related research .
Cat. No.: HY-126929
CAS No.: 81534-36-3
Synonyms: TXN-B
Trioxacarcin B (TXN-B) is a potent cytotoxic agent and DNA-targeted inhibitor. Trioxacarcin B disrupts DNA function and induces apoptosis in cancer cells. Trioxacarcin B not only effectively inhibits the growth of various Gram-positive and Gram-negative bacteria as well as Plasmodium falciparum, but also blocks the colony formation of cancer stem cells, significantly reduces tumor volume and prolongs survival in preclinical in vivo models. The activity of Trioxacarcin B is highly dependent on its intact spiro-epoxide structure; it loses efficacy once this moiety undergoes hydrolysis, and Trioxacarcin B shows no activity against fungi, microalgae and small RNA viruses. Trioxacarcin B can be used for research on bacterial infections, malaria, and various cancers including colon cancer and melanoma .
Cat. No.: HY-L073
394 compounds
Hepatitis C virus (HCV) is a hepatotropic enveloped positive- strand RNA virus (family Flaviviridae) that infects the parenchymal cells of the liver. HCV infection is a significant public health burden. Globally, an estimated 71 million people have chronic hepatitis C virus infection. A significant number of those who are chronically infected will develop cirrhosis or liver cancer. To date, there is no vaccine against HCV, and combination pegylated alpha interferon (pIFN-) and ribavirin, the main standard-of-care treatment for HCV, is effective in only a subset of patients and is associated with a wide spectrum of toxic side effects and complications. More recently, new therapeutic approaches that target essential components of the HCV life cycle have been developed, including direct-acting antiviral (DAA) that specifically block a viral enzyme or functional protein and host-targeted agents (HTA) that block interactions between host proteins and viral components that are essential to the viral life cycle. However, the genetic diversity of HCV viruses and the stage of liver disease (i.e., cirrhosis) are revealing themselves as obstacles for effective, pan-genotypic treatments. There still exists a need for the discovery and development of new HCV inhibitors. In particular, since the future of HCV therapy will likely consist of a cocktail approach using multiple inhibitors that target different steps of infection, new antivirals targeting all steps of the viral infection cycle.
MCE offers a unique collection of 394 compounds with identified and potential anti-HCV activity. MCE Anti- Hepatitis C Virus Compound Library is a useful tool for discovery new anti-HCV drugs and other anti-infection research.
Cat. No.: HY-145973B
Research Areas:
3'OMe-m7GpppAmpG (Tris) is a trinucleotide Cap1 analog with the structure m7 (3'OMeG)(5') ppp (5')(2'OMeA) pG, and also functions as a cis-acting ligase ribozyme inhibitor. 3'OMe-m7GpppAmpG (Tris) effectively reduces free 5'-triphosphate groups on RNA transcripts, thereby enabling efficient co-transcriptional capping of in vitro transcribed mRNA. 3'OMe-m7GpppAmpG (Tris) is not only widely used in the preparation of modified mRNA including trivalent influenza vaccine candidates, but also applicable to studies related to SARS-CoV-2 infection and other relevant research .
Cat. No.: HY-L048
585 compounds
The high rates of morbidity and mortality caused by fungal infections are associated with the current limited antifungal arsenal and the high toxicity of the compounds. Additionally, identifying novel drug targets is challenging because there are many similarities between fungal and human cells. The most common antifungal targets include fungal RNA synthesis and cell wall and membrane components, though new antifungal targets are being investigated. Nonetheless, fungi have developed resistance mechanisms, such as overexpression of efflux pump proteins, overexpression and changes in drug targets and biofilm formation, emphasizing the importance of discovering new antifungal drugs and therapies. Due to the limited antifungal arsenal, researchers have sought to improve treatment via different approaches, such as the combination of antifungal drugs, development of new formulations for antifungal agents and modifications to the chemical structures of traditional antifungals, etc.
MCE offers a unique collection of 585 compounds with validated antifungal activities. MCE antifungal compound library is an effective tool for drug repurposing screening, combination screening and biological investigation.
-
-
Protocols
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!A suitable model is crucial in drug screening experiments. Organs can mimic the three-dimensional functional structure of internal organs, have similar spatial organization to corresponding organs, maintain some key characteristics, and reproduce some physiological functions. They are widely used for modeling and personalized drug screening physiological functions.2025-02-06
